DR-70 test

DR-70 test

An ELISA assay that quantifies fibrin and fibrinogen degradation products in blood, which are increased in various cancers and further increase as the malignancy grows. DR-70 screening is FDA-approved for lung, breast, stomach, liver, colorectal, ovarian, oesophageal, cervical, trophoblastic, thyroid, brain and pancreatic cancers, as well as lymphoma, and may be better at detecting recurrent colorectal cancer than the time-honoured measurement of CEA levels.

Specificity: 95%.
Sensitivity: 84%.

False positives
DR-70 is increased after surgery, chemotherapy and radiotherapy.
References in periodicals archive ?
Clinical trials in other countries show the DR-70 test can detect at least 13 types of cancer.
SURESCREEN Diagnositcs, who own the UK rights to the DR-70 test, say it could be available in the UK by next year in private clinics, hospitals and doctors' surgeries and will cost pounds 50.
The DR-70 test has been developed in the US but could be available in the UK by next year.